iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Biocon Biologics gets marketing approval for YESAFILI; stock trades ~1% higher

15 Nov 2023 , 11:48 AM

Biocon Biologics, a Biocon subsidiary, stated on Monday that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom has given marketing authorization for YESAFILI, an Aflibercept biosimilar.

This clearance followed the European Commission’s (EC) permission for marketing authorization in the European Union (EU) in September.

YESAFILI, an ophthalmology product, is intended to treat a variety of eye conditions, including neovascular (wet AMD) age-related macular degeneration, visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO), diabetic macular oedema (DME), and myopic choroidal neovascularisation (myopic CNV).

The biosimilar is highly comparable to the reference medication Eylea® (aflibercept).

At around 11.44 AM, Biocon was trading 1.21% higher at Rs 230.10, against the previous close of Rs 227.35 on NSE. The counter touched an intraday high and low of Rs 231.75 and Rs 228.45, respectively.

For feedback and suggestions, write to us at editorial@iifl.com

explored-media

Related Tags

  • Biocon
  • Biocon Biologics
  • Biocon Biologics news
  • Biocon Biologics Updates
  • Biocon news
  • Biocon Stock
  • Biocon Updates
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.